Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 Aug 1;108(8):2244-2248.
doi: 10.3324/haematol.2022.282258.

Activity of decitabine combined with all- trans retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER)

Christoph Rummelt  1 , Olga Grishina  2 , Claudia Schmoor  2 , Martina Crysandt  3 , Michael Heuser  4 , Katharina S Götze  5 , Richard F Schlenk  6 , Konstanze Döhner  7 , Helmut R Salih  8 , Gerhard Heil  9 , Carsten Müller-Tidow  10 , Wolfram Brugger  11 , Andrea Kündgen  12 , Maike De Wit  13 , Aristoteles Giagounidis  14 , Sebastian Scholl  15 , Andreas Neubauer  16 , Jürgen Krauter  17 , Gesine Bug  18 , Haifa Kathrin Al-Ali  19 , Ralph Wäsch  1 , Heiko Becker  20 , Annette M May  21 , Justus Duyster  20 , Björn Hackanson  22 , Arnold Ganser  4 , Hartmut Döhner  23 , Michael Lübbert  24
Affiliations
Clinical Trial

Activity of decitabine combined with all- trans retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER)

Christoph Rummelt et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Effects of the addition of all-trans retinoic acid and valproic acid to decitabine on overall survival. (A) Overall survival (OS) according to treatment arms: A: black, B: red, C: blue, D: green. (B) OS according to treatment with decitabine plus all-trans retinoic acid (DEC + ATRA) (+/- valproic acid [VPA]) (red curves) compared to DEC (+/- VPA) (blue curves, Kaplan-Meier method). Solid curves: unadjusted; broken curves: adjustment for Eastern Cooperative Oncology Group performance status, comorbidities (hematopoietic cell transplantation index), serum lactate dehydrogenase, hemoglobin, genetic risk (ELN 2010). (C) OS according to treatment with DEC + VPA (+/- ATRA) (red curves) compared to DEC (+/- ATRA) (blue curves, Kaplan-Meier method). Solid curves: unadjusted; broken curves: Eastern Cooperative Oncology Group performance status, comorbidities (hematopoietic cell transplantation index), serum lactate dehydrogenase, hemoglobin, genetic risk (ELN 2010).
See this image and copyright information in PMC

References

    1. Silverman LR., Demakos EP, Peterson BL, et al. . Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429-2440. - PubMed
    1. Kantarjian H, Issa JPJ, Rosenfeld CS, et al. . Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794-1803. - PubMed
    1. Lübbert M, Suciu S, Baila L, et al. . Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011;29(15):1987-1996. - PubMed
    1. Zeidan AM, Davidoff AJ, Long JB, et al. . Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. Br J Haematol. 2016;175(5):829-840. - PubMed
    1. Maakaron J.E., et al. . Hypomethylating agents super-responders: challenging the dogma of long-term remission for acute myeloid leukemia. Ann. Hematol. 2020;99:1411-1413. - PubMed

Publication types

MeSH terms